Investor Presentation
(NASDAQ: DCTH)
June 2015
1 DELCATH SYSTEMS, INC
Forward-looking Statements
This presentation contains forward-looking statements, within the meaning of the federal securities laws, related to future
events and future financial performance which include statements about our expectations, beliefs, plans, objectives,
intentions, goals, strategies, assumptions and other statements that are not historical facts. Forward-looking statements
are subject to known and unknown risks and uncertainties and are based on potentially inaccurate assumptions, which
could cause actual results to differ materially from expected results, performance or achievements expressed or implied
by statements made herein. Our actual results could differ materially from those anticipated in forward-looking statements
for many reasons, including, but not limited to, uncertainties relating to: the timing and results of future clinical trials
including without limitation the OM, HCC, ICC, and mCRC trials in the Company’s Clinical Development Program, clinical
adoption, use and resulting sales, if any, for the CHEMOSAT system in Europe, our ability to obtain reimbursement for the
CHEMOSAT system in various markets including without limitation Germany and the United Kingdom, our ability to
successfully commercialize the Melphalan/HDS system and the potential of the Melphalan/HDS system as a treatment for
patients with primary and metastatic disease in the liver, the Company's ability to satisfy the requirements of the FDA's
Complete Response Letter relating to the ocular melanoma indication and the timing of the same, approval of the
Melphalan/HDS system by the U.S. FDA, acceptance of the Phase 3 trial publication, the impact of presentations and
abstracts at major medical meetings and congresses (ESSO, SSO, ASCO, CIRSE) and future clinical results consistent
with the data presented, approval of the current or future Melphalan/HDS system for delivery and filtration of melphalan or
other chemotherapeutic agents for various indications in the U.S. and/or in foreign markets, actions by the FDA or other
foreign regulatory agencies, our ability to successfully enter into strategic partnership and distribution arrangements in
foreign markets and the timing and revenue, if any, of the same, uncertainties relating to the timing and results of research
and development projects, and uncertainties regarding our ability to obtain financial and other resources for any clinical
trials, research, development, and commercialization activities. These factors, and others, are discussed from time to time
in our filings with the Securities and Exchange Commission including the section entitled ‘‘Risk Factors’’ in our most
recent Annual Report on Form 10-K and our Reports on Form 10-Q and Form 8-K.
2 DELCATH SYSTEMS, INC
About Delcath Systems
• 
A specialty pharmaceutical and medical device oncology company with a
principal therapeutic focus on the treatment of primary liver cancer and other
cancers that have metastasized to the liver
• 
Proprietary system isolates the liver from circulation, delivers a substantially
higher concentration of chemotherapy (melphalan) compared with systemic
doses, and filters most of the chemotherapy out of the blood prior to returning
it to the patient
• 
In late-stage clinical development in the U.S. with initial commercial activities
underway in Europe
• 
Initially pursuing orphan indications in metastatic ocular melanoma,
hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC)
Seeking to Make a Clinically Meaningful Difference For Cancer Patients With Liver Dominant Disease
3 DELCATH SYSTEMS, INC
Investment Highlights
•  Late-stage asset – approved and initial commercial activities underway in
EU; demonstrated clinically meaningful efficacy in more than 600 procedures
and multiple tumor types
•  Active clinical program – initiating global Phase 3 study in ocular
melanoma; HCC/ICC Phase 2 program ongoing
•  Unique, highly differentiated solution – orphan designations create
barriers to entry
•  Large market opportunity – cancers of the liver remain a multibillion-dollar
unmet medical need; early commercial activity EU
•  Imminent valuation milestones – 2015 value drivers include publications,
reimbursement and clinical data
•  Attractive business model – initial orphan focus and anticipated high
gross margins form basis of profitable long-term model
•  Experienced management team – aligned with requirements of clinically
driven pharmaceutical industry
Large, Compelling Market Opportunity
4 DELCATH SYSTEMS, INC
2014-2015 Milestones
2014 Accomplishments
ü 
ü 
ü 
ü 
ü 
Phase 2 HCC trial open and first patient treated
100th patient treated in Europe (commercial and clinical)
Positive efficacy data from three institutions presented at ESSO 2014
Product revenue increased 118% Y/Y to $1.1 million
Cash burn reduced by 50% Y/Y
1H-2015
ü 
ü 
ü 
ü 
NUB reimbursement decision in Germany – Value 4 awarded for 2015
Submit Phase 3 metastatic melanoma trial results for publication
EU registry open for enrollment
ICC cohort open for enrollment
2H-2015
o  Initiation of global Phase 3 metastatic ocular melanoma program
o  Interim evaluation on HCC/ICC program
Executing on Multiple Fronts to Create Value
5 DELCATH SYSTEMS, INC
The Liver: A Life-Limiting Organ
•  Cancers of the liver remain a major unmet medical need
o  Large global patient population – approximately 1.2 million* patients
diagnosed annually with primary or metastatic liver cancer
o  The liver is often the life-limiting organ for cancer patients and one of the
leading causes of cancer death
o  Prognosis after liver involvement is poor, with overall survival generally
less than 12 months
•  CHEMOSAT® Melphalan/HDS is a proprietary product uniquely
positioned to potentially treat the entire liver as a standalone or
complementary therapy
Effective Liver Cancer Treatment Remains a Major Unmet Medical Need
* SOURCE – 2008 GLOBOCAN
6 DELCATH SYSTEMS, INC
Our Solution: Whole Organ-Focus Disease Control
•  Our proprietary system isolates the liver circulation, delivers a
high concentration of chemotherapy (melphalan) and filters
most of the chemotherapy out of the blood prior to returning it
to the patient
•  The procedure typically takes approximately 2-3 hours to
complete and involves a team including the interventional
radiologist and perfusionist
•  We believe more than 200 treatments with improved device
and procedure in the U.S. and EU provide confidence safety
can be validated in a controlled setting
Concentrating the Power of Chemotherapy for Disease Control in the Liver
7 DELCATH SYSTEMS, INC
Existing Liver Cancer Treatments Landscape
Treatment
Systemic
Advantages
Disadvantages
–  Non-invasive
–  Systemic toxicities
–  Repeatable
–  Limited efficacy in liver
Regional
–  Therapeutic effect
(e.g., Isolated Hepatic Perfusion)
–  Targeted
–  Invasive/limited repeatability
–  Multiple treatments are required
but not possible
–  Only 10%-20% are resectable
–  Invasive and/or limited
repeatability
Focal
(e.g., surgery, radioembolization,
chemoembolization,
radiofrequency ablation)
–  Partial removal or
treatment of tumors
–  Treatment is limited by tumor
size, number of lesions and
location
–  Tumor revascularization
–  Cannot treat diffuse disease
Existing Liver Cancer Treatments Have Limitations
8 DELCATH SYSTEMS, INC
The Melphalan Hepatic Delivery System (HDS)
Liver Isolated Via Double Balloon
Catheter In IVC
Melphalan Infused Directly Into Liver
Via Catheter In Hepatic Artery
Blood Exiting The Liver Filtered By
Proprietary Extra-corporeal Filters
•  Device designed to administer high-dose chemotherapy to the liver while reducing
systemic exposure
•  Marketed as Delcath Hepatic CHEMOSAT® Delivery System (device only) in EU
•  Investigational drug/device combination product regulated as a drug in the U.S.
More Than 300 Patients Treated To Date
9 DELCATH SYSTEMS, INC
Melphalan Dosing & Background
Type
Dosing (mg/kg)
Multiple Myeloma (label)
0.25
Chemoembolization
0.62
Surgical Isolated Hepatic Perfusion (IHP)
1.50
Myeloablation
2.50-3.50
Chemosaturation (PHP)
3.00
• 
Well-understood, dose-dependent, tumor-preferential, alkylating cytotoxic agent
that demonstrates little to no hepatic toxicity
• 
Dose administered directly to liver is substantially higher than that of systemic IV
chemotherapy
• 
Melphalan, an established chemotherapy agent, is proven active at high doses
with broad antitumor activity
An Established Drug for Liver Cancer Therapy
10 DELCATH SYSTEMS, INC
Total Available EU & U.S. Market Opportunity
Cancer Type
Annual Potential
Market Opportunity
3,5
(millions)
Annual Potential
Market Opportunity
4,5
(millions)
2,600-4,300
6,500
7,600-14,700
40,000-55,000
$104-$215
$260-$330
$304-$735
$1,600-$2,750
$208-$430
$520-$660
$608-$1,470
$3,200-$5,500
492,700-495,600 56,700-80,500
$2,268-$4,030
$4,536-$8,060
Annual
1
Incidence
Ocular Melanoma (OM)
5,700-8,600
Cholangio Carcinoma (ICC)
11,500
Hepatocellular Carcinoma (HCC)
64,500
Colorectal (CRC)
411,000
Total EU and US
Eligible Pts
2
Notes:
1) Source: Globocan, American Cancer Society
2) Source: LEK, Strategy&, Company estimates
3 ) Assumes an average of tw o treatments per patient
4 ) Assumes an average of four treatments per patient
5 ) Assumes $20,000-$25,000 USD per treatment
Cancers Of The Liver Remain a Multibillion-Dollar Unmet Medical Need
11 DELCATH SYSTEMS, INC
Clinically Differentiated Results
• 
• 
Phase 1, 2 and 3 trials produced positive results in multiple histologies
Melanoma Liver Mets
o  Positive Phase 3 results in hepatic metastatic melanoma
o  n=93 (90% ocular melanoma, 10% cutaneous melanoma)
• 
Neuroendocrine Tumor (NET) Liver Mets
o  mNET cohort in Phase 2 trial showed encouraging 42% objective response rate
(ORR) vs. ~10% for approved targeted therapy
o  Median overall survival of ~32 months on ITT basis
• 
Hepatocellular Carcinoma (HCC)
o  Positive signal with high-dose melphalan in HCC cohort of Phase 2 trial (5/8 patients)
is encouraging when approved systemic therapies have modest efficacy and
challenges with tolerability
• 
Colorectal Cancer (CRC) Liver Mets
o  Data from surgical Isolated Hepatic Perfusion (IHP) with melphalan indicates strong
potential in well-defined patient population with earlier stage CRC yielding ~50-60%
median response rate and median OS of 17.4-24.8 mos
Encouraging Initial Results on a Broad Range of Histologies
12 DELCATH SYSTEMS, INC
Clinical Development Program Detail
Trials Phase 3 Pivotal Trial Tumor OM liver mets Phase 2 Trial HCC (unresectable conﬁned to the liver) Phase 2 Cohort ICC (unresectable conﬁned to the liver) Inves0gator Ini0ated Trials mCRC HCC EU Commercial EU Commercial Registry SYSTEMS, INC
Cases 13 DELCATH
Objec0ves § 
§ 
§ 
Global Phase 3 trial to start 2H-‐2015 Primary endpoint: Overall Survival (OS) Believed to be fastest pathway to NDA approval in the U.S. § 
§ 
Protocol 201 (U.S. only) Safety, eﬃcacy of melphalan/HDS treatment followed by sorafenib §  Evaluate ORR (mRECIST) §  Assess safety, PFS §  Characterize systemic exposure of melphalan §  Assess pa0ent QoL
§ 
§ 
Protocol 202 (EU only) Safety, eﬃcacy of melphalan/HDS treatment w/o sorafenib in pa0ents with unresectable liver cancer §  Evaluate ORR (mRECIST) §  Assess safety, PFS §  Characterize systemic exposure of melphalan §  Assess pa0ent QoL § 
§ 
Added to 202 HCC trial protocol ORR of melphalan/HDS treatment in pa0ents with intra‑hepa0c cholangiocarcinoma (ICC) §  Other measures as speciﬁed in the 202 EU protocol §  Signal-‐seeking go/no-‐go decision 2H -‐ 2015 §  University of Leiden study; ~7 pa0ents treated to date §  Johannes Wolfgang Goethe University Hospital (Frankfurt) study; diﬀerent pa0ent selec0on from 202 study; open for enrollment § 
§ 
§ 
Data collec0on on safety, QoL assessments Poten0al eﬃcacy signals in addi0onal tumor types Support reimbursement in key markets OM Metastases Rationale
• 
• 
• 
• 
• 
OM has high incidence of liver metastases
o  Up to 90% of patients with metastases will have liver involvement
o  Life expectancy of approximately 6 months
o  5,700 - 8,600 cases of OM liver metastases diagnosed in U.S. and EU
annually
Clear efficacy signal seen in prior Phase 3 trial of melphalan/HDS
Currently no standard of care
Believed to be fastest pathway to NDA approval in the U.S.
FDA granted melphalan/HDS orphan drug designation for treatment of OM
U.S./EU Market Size
5,700-8,600
Cases of Ocular
Melanoma
~50-55%
Metastasize
~90%
Show Liver Mets
Limited TX Options
~2,600 – 4,300
Eligible Patients
Proven Efficacy in Attractive Orphan Opportunity
14 DELCATH SYSTEMS, INC
*Sources: ACS, SEER, NIH, OMF, KOL Interviews, 2014 3rd Party
Analysis
Previous Ocular Melanoma Mets Phase 3 Results
Overall Progression Free Survival (Investigator)
Hepatic Progression Free Survival (hPFS)
Propor/on of pa/ents surviving Propor/on of pa/ents surviving 1.0 1.0 5.3 mo 3.8 mo Chemosatura0on (CS-‐PHP) 0.8 Best alterna0ve care (BAC) 0.8 Chemosatura0on (CS-‐PHP) Best alterna0ve care (BAC) 0.6 0.6 1.7 0.4 7.0 0.4 0.2 0.2 0.0 0.0 0
5
10 1.6 15 20 25 Months 30 0
5
5.4 10 15 20 25 30 35 40 45 50 55 Months Intent-‐to-‐Treat Analysis (June 2012) § 
§ 
§ 
§ 
Intent-‐to-‐Treat Analysis (June 2012) 4 subjects remain
alive at 5-8 years
5.3 mos improvement in hPFS All were recipients §  3.8 mos improvement in PFS
Hazard ratio = 0.50
§  Hazard ratio = 0.42
of CS-PHP
(95% CI 0.31–0.80)
§  (95% CI 0.27–0.64)
p=0.0029
§  p<0.0001
Clinically Meaningful Benefit Previously Demonstrated for Metastatic OM Patients
15 DELCATH SYSTEMS, INC
ICC Rationale
•  Significant market opportunity in U.S. and EU
o  ~15% of new HCC cases diagnosed annually
o  ~90% of patients are not suitable for surgical resection
o  ~20-30% are candidates for focal interventions
o  Efficacy signals from early commercial uses in EU
•  Unmet medical need – Delcath is pursuing a melphalan orphan
drug designation from the FDA for patients with ICC
U.S./EU Market Size
76,000
HCC Diagnosis
~15%
Of HCC
Cases
~90%
Unresectable
~20-30%
Focal
Interventions
~6,500
Eligible Patients
Encouraging Early Commercial Activity in Disease With Limited Treatment Options
16 DELCATH SYSTEMS, INC
*Sources: ACS, SEER, NIH, KOL Interviews, 2014 3rd Party Analysis
HCC Rationale
• 
• 
• 
Significant opportunity in the U.S. and EU
o  HCC most common primary cancer of the liver
o  ~76,000* cases diagnosed annually
Large unmet medical need in first-line therapy
o  Only one approved systemic therapy in the U.S., EU and certain Asian
markets
o  ~90% of patients not candidates for surgical resection
o  20-30% of patients are candidates for focal interventions
FDA granted melphalan/HDS orphan drug designation for treatment of
unresectable HCC
U.S./EU Market Size
76,000
Cases of Primary Liver
Cancer
~90%
HCC
~80-90%
Unresectable
~20-30%
Interventional
TX
~20-30%
Child Pugh Class A
~7,600 – 14,700
Eligible Patients
Large, Deadly Disease in Need of Better Treatments
17 DELCATH SYSTEMS, INC
*Sources: WHO, KOL Interviews, 2014 3rd Party Analysis
Prior FDA Experience
•  New Drug Application (NDA) submitted August 2012 seeking
indication in OM liver metastases with first-generation filters
and procedure
•  ODAC meeting in May 2013
o  Efficacy shown with statistical significance
o  Negative vote due to benefit/risk analysis
o  Complete FDA & Delcath ODAC briefing materials available at
www.delcath.com/clinical-research/clinical-bibliography/
•  Complete Response Letter (CRL) issued September 2013
•  FDA requests include, but not limited to:
o  Well-controlled randomized trial(s) to establish the safety and
efficacy using the to-be-marketed device configuration
o  Overall survival as the primary efficacy outcome measure
o  Demonstrate clinical benefits outweigh risks
FDA Learnings Provide Beneficial Clinical Study Roadmap
18 DELCATH SYSTEMS, INC
Risks Observed in Previous Clinical Program
• 
Risks observed with prior product and procedure protocol
• 
Integrated safety population of patients showed risks associated with
melphalan/HDS included:
o  4.1% incidence of death due to adverse reactions
o  4% incidence of stroke
o  2% reported incidence of myocardial infarction in the setting of an incomplete cardiac
risk assessment
o  ≥70% incidence of grade 4 bone marrow suppression with a median time of recovery
of greater than 1 week
o  18% incidence of febrile neutropenia, along with the additive risk of hepatic injury,
severe hemorrhage and gastrointestinal perforation
•  Deaths due to certain adverse reactions did not occur again during the clinical
trials following the adoption of related protocol amendments
Treating Physicians in U.S. and EU Report Improved Safety Profile
19 DELCATH SYSTEMS, INC
Safety Improvements Implemented
•  New generation filter
o  Improve filter efficiency and consistency
•  Vasopressors and methylprednisolone
o  Reduce cardiovascular risk
•  Prophylactic transfusions and growth factors
o  Reduce risk of myelosuppression
•  Intra-arterial nitroglycerin
o  Prevent hepatic arterial spasm
•  Liver tumor burden not to exceed >50%
o  Address risk of liver failure
Decisive Measures to Assure Improved Safety
20 DELCATH SYSTEMS, INC
Positive Developments
• 
Improved device and procedure since prior trials
o  >200 treatments with improved device and procedure in U.S. and EU
o  Many issues raised at ODAC have not been reported
• 
Current device/procedure permitting multiple treatment cycles
• 
Recent Presentations & Abstracts at Major Medical Meetings/Congresses
o 
o 
o 
o 
• 
ESSO 2014
SSO 2015
ASCO 2015
CIRSE 2015
Data consistent with observations from EU commercial experience
Patients Report Improved Quality of Life
21 DELCATH SYSTEMS, INC
Recent Data Presentations - ASCO 2015
• 
Analysis of 20 patients who received 34 treatments at Southampton
University Hospital
o  Eleven patients remain alive after a median of 280 days with one complete
response ongoing at >1 year
o  From the diagnosis of liver metastases, 11 patients (55%) survived to one year and
3 (15%) for >2 years; no procedure related deaths were seen
o  2 patients (10%) demonstrated stable disease for >3 months, 13 patients (65%)
had a partial response, 2 patients (10%) demonstrated complete response
o  Nine deaths from disease progression occurred after a median of 264 days from
the first procedure
• 
Adverse Events
o  Early AEs often expected with percutaneous hepatic perfusion (PHP) were
observed including coagulopathy, electrolyte disturbances and transient
transaminases (elevated liver enzymes). Rare late AEs (1 patient each) included
hair loss, skin rash, myelosuppression and persistent transaminases (elevated liver
enzymes)
o  AEs seen were grade 1 (n=12), 2 (n=13), 3 (n=5) and 4 (n=1)
o  Grade 4 complication was pulmonary edema due to fluid overload
22 DELCATH SYSTEMS, INC
Recent Data Presentations - SSO 2015
• 
Moffitt Cancer Center (Tampa, FL)
o  Retrospective analysis of 30 patients with ocular or cutaneous melanoma treated
with Melphalan/HDS (n=10), chemoembolization (CE, n=12), and yttrium-90 (Y90,
n=6)
o  Study showed significant difference in hepatic progression free survival (HPFS) for
Melphalan/HDS (310 days), CE (80 days), Y-90 (54 days)
o  Median overall survival (OS) longest for Melphalan/HDS (736 days) vs Y90 (285
days) CE (265 days), but did not reach statistical significance
o  Authors concluded that HPFS and progression free survival (PFS) were
significantly prolonged with Melphalan/HDS vs CE and Y90
23 DELCATH SYSTEMS, INC
European Commercial Activity
CHEMOSAT®
Hepatic Delivery System
•  Approved as Class IIb Medical Device; kit
supplied without melphalan
•  Broad indication for intra-hepatic
administration of melphalan hydrochloride and
subsequent filtration of the venous blood
return
•  >180 commercial procedures performed in
leading cancer centers across the EU
•  Reimbursement via Individual Funding
Requests; NUB Value 4 Status in Germany
•  UK Block Grants pending and private pay
insurance
•  Published data in peer-reviewed journal
needed to support reimbursement efforts in
certain EU countries
24 DELCATH SYSTEMS, INC
CHEMOSAT® Commercial Treatments in Europe
Multiple Tumor Types Treated Since EU Launch
TREATMENTS
DISEASE (Commercial Treatments)
160 140 200 136 175 120 150 100 125 80 111 100 60 75 40 20 186 9 19 2 0 2 3 1 6 6 1 1 25 0 Treatments/Re-treatments Increasing
25 DELCATH SYSTEMS, INC
52 50 20 3 Cash & Capital Resources
Cash & Cash Equivalents
$18.5 million at March 31, 2015
Debt
None
ATM Program1
$40 million available at March 31, 2015
Shares Outstanding
12.2 million (14.4 million fully diluted2) at
March 31, 2015
1)  Subject to market conditions and certain limitations
2)  Fully diluted includes approximately 0.3 million options and 1.9 million warrants
Focused Spending and Resources to Support Execution of Near-term Plan
26 DELCATH SYSTEMS, INC
In Summary
Melphalan Hydrochloride for Injec/on for use with the Delcath Hepa/c Delivery System (Melphalan/HDS) •  Cancers of the liver remain a
multibillion-dollar unmet medical
need
•  Unique, highly differentiated solution
•  Late-stage asset in U.S., early
commercial activity EU
•  Compelling emerging data
•  Imminent valuation milestones
•  Attractive orphan drug business
model
•  Experienced pharmaceutical
management team executing a
data-driven plan
27 DELCATH SYSTEMS, INC
©
DELCATH
SYSTEMS,
282015
DELCATH
SYSTEMS,
INC INC. ALL RIGHTS RESERVED
Delcath and CHEMOSAT are registered trademarks of Delcath Systems, Inc.